Volumetric Description of Brain Atrophy in Neuronal Ceroid Lipofuscinosis 2: Supratentorial Gray Matter Shows Uniform Disease Progression

References

1. 1.↵
   2. Haltia M,
   3. Goebel HH

   . The neuronal ceroid-lipofuscinoses: a historical introduction. Biochim Biophys Acta 2013;1832:1795–800 doi:10.1016/j.bbadis.2012.08.012 pmid:22959893

   CrossRefPubMed
2. 2.↵
   2. Warrier V,
   3. Vieira M,
   4. Mole SE

   . Genetic basis and phenotypic correlations of the neuronal ceroid lipofusinoses. Biochim Biophys Acta 2013;1832:1827–30 doi:10.1016/j.bbadis.2013.03.017 pmid:23542453

   CrossRefPubMed
3. 3.↵
   2. Kousi M,
   3. Lehesjoki AE,
   4. Mole SE

   . Update of the mutation spectrum and clinical correlations of over 360 mutations in eight genes that underlie the neuronal ceroid lipofuscinoses. Hum Mutat 2012;33:42–63 doi:10.1002/humu.21624 pmid:21990111

   CrossRefPubMed
4. 4.↵
   2. Jadav RH,
   3. Sinha S,
   4. Yasha TC, et al

   . Clinical, electrophysiological, imaging, and ultrastructural description in 68 patients with neuronal ceroid lipofuscinoses and its subtypes. Pediatr Neurol 2014;50:85–95 doi:10.1016/j.pediatrneurol.2013.08.008 pmid:24120650

   CrossRefPubMed
5. 5.↵
   2. Bessa C,
   3. Teixeira CA,
   4. Dias A, et al

   . CLN2/TPP1 deficiency: the novel mutation IVS7–10A>G causes intron retention and is associated with a mild disease phenotype. Mol Genet Metab 2008;93:66–73 doi:10.1016/j.ymgme.2007.08.124 pmid:17959406

   CrossRefPubMed
6. 6.↵
   2. Elleder M,
   3. Dvoráková L,
   4. Stolnaja L, et al

   . Atypical CLN2 with later onset and prolonged course: a neuropathologic study showing different sensitivity of neuronal subpopulations to TPP1 deficiency. Acta Neuropathol (Berl) 2008;116:119–24 doi:10.1007/s00401-008-0349-3 pmid:18283468

   CrossRefPubMedWeb of Science
7. 7.↵
   2. Kohan R,
   3. Carabelos MN,
   4. Xin W, et al

   . Neuronal ceroid lipofuscinosis type CLN2: a new rationale for the construction of phenotypic subgroups based on a survey of 25 cases in South America. Gene 2013;516:114–21 doi:10.1016/j.gene.2012.12.058 pmid:23266810

   CrossRefPubMed
8. 8.↵
   2. Schulz A,
   3. Kohlschütter A,
   4. Mink J, et al

   . NCL diseases: clinical perspectives. Biochim Biophys Acta 2013;1832:1801–06 doi:10.1016/j.bbadis.2013.04.008 pmid:23602993

   CrossRefPubMed
9. 9.↵
   2. Paniagua Bravo A,
   3. Forkert ND,
   4. Schulz A, et al

   . Quantitative T2 measurements in juvenile and late infantile neuronal ceroid lipofuscinosis. Clin Neuroradiol 2013;23:189–96 doi:10.1007/s00062-012-0189-3 pmid:23263384

   CrossRefPubMed
10. 10.↵
    2. Dyke JP,
    3. Voss HU,
    4. Sondhi D, et al

    . Assessing disease severity in late infantile neuronal ceroid lipofuscinosis using quantitative MR diffusion-weighted imaging. AJNR Am J Neuroradiol 2007;28:1232–36 doi:10.3174/ajnr.A0551 pmid:17698521

    Abstract/FREE Full Text
11. 11.↵
    2. Autti T,
    3. Raininko R,
    4. Santavuori P, et al

    . MRI of neuronal ceroid lipofuscinosis, II: postmortem MRI and histopathological study of the brain in 16 cases of neuronal ceroid lipofuscinosis of juvenile or late infantile type. Neuroradiology 1997;39:371–77 doi:10.1007/s002340050427 pmid:9189886

    CrossRefPubMedWeb of Science
12. 12.↵
    2. Löbel U,
    3. Sedlacik J,
    4. Güllmar D, et al

    . Diffusion tensor imaging: the normal evolution of ADC, RA, FA, and eigenvalues studied in multiple anatomical regions of the brain. Neuroradiology 2009;51:253–63 doi:10.1007/s00234-008-0488-1 pmid:19132355

    CrossRefPubMedWeb of Science
13. 13.↵
    2. Autti TH,
    3. Hämäläinen J,
    4. Mannerkoski M, et al

    . JNCL patients show marked brain volume alterations on longitudinal MRI in adolescence. J Neurol 2008;255:1226–30 doi:10.1007/s00415-008-0891-x pmid:18677643

    CrossRefPubMed
14. 14.↵
    2. Dyke JP,
    3. Sondhi D,
    4. Voss HU, et al

    . Assessment of disease severity in late infantile neuronal ceroid lipofuscinosis using multiparametric MR imaging. AJNR Am J Neuroradiol 2013;34:884–89 doi:10.3174/ajnr.A3297 pmid:23042927

    Abstract/FREE Full Text
15. 15.↵
    2. Steinfeld R,
    3. Heim P,
    4. von Gregory H, et al

    . Late infantile neuronal ceroid lipofuscinosis: quantitative description of the clinical course in patients with CLN2 mutations. Am J Med Genet 2002;112:347–54 doi:10.1002/ajmg.10660 pmid:12376936

    CrossRefPubMedWeb of Science
16. 16.↵
    2. Fischl B

    . FreeSurfer. Neuroimage 2012;62:774–81 doi:10.1016/j.neuroimage.2012.01.021 pmid:22248573

    CrossRefPubMedWeb of Science
17. 17.↵
    2. Smith SM

    . Fast robust automated brain extraction. Hum Brain Mapp 2002;17:143–55 doi:10.1002/hbm.10062 pmid:12391568

    CrossRefPubMedWeb of Science
18. 18.↵
    2. Worgall S,
    3. Kekatpure MV,
    4. Heier L, et al

    . Neurological deterioration in late infantile neuronal ceroid lipofuscinosis. Neurology 2007;69:521–35 doi:10.1212/01.wnl.0000267885.47092.40 pmid:17679671

    Abstract/FREE Full Text
19. 19.↵
    2. Anderson GW,
    3. Goebel HH,
    4. Simonati A

    . Human pathology in NCL. Biochim Biophys Acta 2013;1832:1807–26 doi:10.1016/j.bbadis.2012.11.014 pmid:23200925

    CrossRefPubMedWeb of Science
20. 20.↵
    Brain Development Cooperative Group. Total and regional brain volumes in a population-based normative sample from 4 to 18 years: the NIH MRI Study of Normal Brain Development. Cereb Cortex 2012;22:1–12 doi:10.1093/cercor/bhr018

    Abstract/FREE Full Text